Bionano Genomics announces second Category I CPT code for OGM

Bionano Laboratories announced that the editorial panel of the American Medical Association established a new Category I Current Procedural Terminology code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV LDTs from third party payers. The Category I CPT code is expected to be included in the next CPT codebook and to be effective January 1, 2026. The establishment of this CPT code for OGM is the second Category I CPT code issued for OGM and follows code 81195, which was established in 2024 for cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. Acceptance of the application for a Category I CPT code in another area of clinical genetic testing with OGM implies that it has met the Category I standards, which are generally considered to be more rigorous than those of Category III codes, which are commonly applied to emerging technologies. As part of the application review process, the panel collects input from stakeholders across the health care community to ensure CPT content reflects the coding and data-driven demands of modern health care.